fda glp-1 compounding enforcement september 2025 Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide What Patients Need to Know

Data Availability Statement The data supporting this study are available upon request to the corresponding author

The constipation pathway: Predominant GLP-1 receptor expression in the colon Slowed peristalsis exceeds the gut's ability to adapt Increased water absorption Hard, infrequent stools The diarrhea pathway: Predominant GLP-1 receptor expression in the small intestine Slowed small bowel transit allows bacterial overgrowth or malabsorption Osmotic load in the colon from unabsorbed nutrients Loose, frequent stools The mixed pathway (most common): Early diarrhea (weeks 1-4) from acute gastric retention and bile acid malabsorption Transition to constipation (weeks 4-12) as colonic adaptation lags behind gastric adaptation Resolution to normal or near-normal bowel habits after 12-16 weeks A 2024 paper in Gut (Acosta et al.) measured GLP-1 receptor density in colonic biopsies from 86 patients starting semaglutide

Moreover, given the high plasma concentrations of endogenous albumin (40 mg/mL) 1 , the competitive pressure on the albumin binding site of FcRn is substantial 11

Vitiligo patches appear with sharp contrast against normal skin

GLP-1s: A Targeted Intervention with Limitations Glucagon-like peptide-1 (GLP-1) medications, which mimic natural hormones, offer valuable support by regulating appetite, blood sugar, and energy expenditure